Literature DB >> 17953663

Progranulin: normal function and role in neurodegeneration.

Jason L Eriksen1, Ian R A Mackenzie.   

Abstract

Progranulin (PGRN) is a multifunctional protein that has attracted significant attention in the neuroscience community following the recent discovery of PGRN mutations in some cases of frontotemporal dementia. Most of the pathogenic mutations result in null alleles, and it is thought that frontotemporal dementia in these families results from PGRN haploinsufficiency. The neuropathology associated with PGRN mutations is characterized by the presence of tau-negative, ubiquitin-immunoreactive neuronal inclusions (frontotemporal lobar degeneration with ubiquitinated inclusions) that are also positive for the transactivation response DNA binding protein with M(r) 43 kD. The clinical phenotype includes behavioral abnormalities, language disorders and parkinsonism but not motor neuron disease. There is significant clinical variation between families with different PGRN mutations and among members of individual families. The normal function of PGRN is complex, with the full-length form of the protein having trophic and anti-inflammatory activity, whereas proteolytic cleavage generates granulin peptides that promote inflammatory activity. In the periphery, PGRN functions in wound healing responses and modulates inflammatory events. In the CNS, PGRN is expressed by neurons and microglia; consequently, reduced levels of PGRN could affect both neuronal survival and CNS inflammatory processes. In this review, we discuss current knowledge of the molecular genetics, neuropathology, clinical phenotype and functional aspects of PGRN in the context of neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17953663     DOI: 10.1111/j.1471-4159.2007.04968.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  58 in total

1.  Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling.

Authors:  Ezra Y Rosen; Eric M Wexler; Revital Versano; Giovanni Coppola; Fuying Gao; Kellen D Winden; Michael C Oldham; Lauren Herl Martens; Ping Zhou; Robert V Farese; Daniel H Geschwind
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 2.  The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases.

Authors:  John R Finnerty; Wang-Xia Wang; Sébastien S Hébert; Bernard R Wilfred; Guogen Mao; Peter T Nelson
Journal:  J Mol Biol       Date:  2010-08-01       Impact factor: 5.469

Review 3.  New approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degeneration.

Authors:  Jill S Goldman
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

Review 4.  Update on Hippocampal Sclerosis.

Authors:  Juliana R Dutra; Etty P Cortés; Jean Paul G Vonsattel
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

5.  Human angiogenin presents neuroprotective and migration effects in neuroblastoma cells.

Authors:  Goang-Won Cho; Byung Yong Kang; Seung Hyun Kim
Journal:  Mol Cell Biochem       Date:  2010-02-20       Impact factor: 3.396

Review 6.  Potential roles of microglial cell progranulin in HIV-associated CNS pathologies and neurocognitive impairment.

Authors:  Hyeon-Sook Suh; Benjamin B Gelman; Sunhee C Lee
Journal:  J Neuroimmune Pharmacol       Date:  2014-03       Impact factor: 4.147

7.  No major progranulin genetic variability contribution to disease etiopathogenesis in an ALS Italian cohort.

Authors:  Roberto Del Bo; Stefania Corti; Domenico Santoro; Isabella Ghione; Chiara Fenoglio; Serena Ghezzi; Michela Ranieri; Daniela Galimberti; Michelangelo Mancuso; Gabriele Siciliano; Chiara Briani; Luigi Murri; Elio Scarpini; Jennifer C Schymick; Bryan J Traynor; Nereo Bresolin; Giacomo P Comi
Journal:  Neurobiol Aging       Date:  2009-07-25       Impact factor: 4.673

Review 8.  Update on recent molecular and genetic advances in frontotemporal lobar degeneration.

Authors:  Eileen H Bigio
Journal:  J Neuropathol Exp Neurol       Date:  2008-07       Impact factor: 3.685

Review 9.  Neurodegenerative dementia and parkinsonism.

Authors:  A Gabelle; F Portet; C Berr; J Touchon
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

Review 10.  Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia.

Authors:  Edward D Huey; Nicole Armstrong; Parastoo Momeni; Jordan Grafman
Journal:  Expert Opin Ther Targets       Date:  2008-11       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.